Athersys: EMA Issues Positive Opinion On MultiStem Cell Therapy

(RTTNews) - Athersys Inc. (ATHX) announced the Committee for Orphan Medicinal Products of the European Medicines Agency has issued a positive opinion for the company's allogeneic, multipotent adult progenitor cell, or MultiStem therapy, for the prevention of graft-versus-host disease, or GvHD. The MultiStem therapy has previously been granted orphan drug designation by the U.S. FDA.

Athersys is developing its MultiStem cell therapy as a GvHD prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplant and is currently preparing for a Phase II/III clinical study in the area.